Asset
TINLAREBANT
BELITE BIO INC AMERICAN DEPOSITARY SHARES
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06388083 | phase2_3 | active_not_recruiting | 2024-07-31 | 2028-02-01 | Belite Bio, Inc | A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease |
| NCT05244304 | phase3 | completed | 2022-03-28 | 2025-08-04 | Belite Bio, Inc | Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Adolescent Stargardt Disease |
| NCT05949593 | phase3 | active_not_recruiting | 2023-07-27 | 2027-06-30 | Belite Bio, Inc | Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy |
| NCT04005807 | phase1 | completed | 2019-07-19 | 2019-12-20 | Belite Bio, Inc | Safety and Tolerability of Escalating Doses of BPN-14967 in Healthy Adults |
FDA applications (0)
This company has no applications containing this asset.